About Neucyte
Neucyte is a Healthcare company based in Sunnyvale (United States) founded in 2015 by Tao Huang. Tools for neural cell production are developed using reprogramming technology. Neucyte has raised $6.7 million across 2 funding rounds from investors including HHS, Co-win Ventures and Leaguer. The company has 10 employees. Neucyte offers products and services including SynFire Technology and MaxTwo Microelectrode Arrays. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is NEUCYTE, INC. Its competitors include Vivodyne, NextVivo and Adapsyn; 2 of its 3 listed competitors have raised funding.
Company details
Neucyte was founded in 2015 and is located in Sunnyvale, United States, within the biotechnology sector focused on neuroscience. Reprogramming technology is utilized to generate homogenous populations of various neuronal subtypes. Human neural in vitro systems are offered for evaluating higher-order electrophysiology, which aids in predicting drug efficacy and assessing potential CNS safety or toxicology risks. Human-specific neural phenotypes are examined through this platform, features absent in animal models.
- Headquarters Sunnyvale, United States
- Employees 10
- Founders Tao Huang
- SectorsHealthcare
- Email••••••••
- Website neucyte.com
- Social LinkedIn X
- Legal Name Neucyte, Inc.
- Total Equity Funding$6.7M (USD)
in 2 rounds
- Latest Funding Round$500K (USD), Grant
Sep 2024
- InvestorsHHS
& 2 more
- Employee Count10
Products & Services of Neucyte
Neucyte offers a comprehensive portfolio of products and services, including SynFire Technology and MaxTwo Microelectrode Arrays.
Generates iPSC-derived neurons for CNS target validation.
Enables functional characterization of neural cells in assays.
Funding Insights of Neucyte
Neucyte has successfully raised a total of $6.7M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $500 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.7M
- Total Rounds 2
- Last Round Grant — $500,000
- First Round $6.7M
(May 2018)
- Investors Count 3
All 2 funding rounds of Neucyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $500,000 | Grant | – | – | |
| May 2018 | $6.7M | Series A | – | Co-win Ventures, Leaguer Group | – |
3 investors in total: 3 institutional.
Investors in Neucyte
Neucyte has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Co-win Ventures and Leaguer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC fund investing in startups | cowinvc.com | Suzhou, China | ||
Leaguer is engaged in technology transfer and innovation services. | leaguer.com.cn | Shenzhen, China | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Neucyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neucyte
7 people are tracked at Neucyte (4 in leadership, 3 in board & advisors); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Tao Huang | Co-Founder & President | Leadership |
Wayne Poon | Head, Neuroscience | Leadership |
Hui Liu | Director, Drug Discovery | Leadership |
Daniel Haag | Head of Neuroscience and Co-Founder | Leadership |
Jennifer Moore | Scientific Advisor | Board & advisors |
Paul J. Hagerman | Scientific Advisor | Board & advisors |
Ellen Fritsche | Scientific Advisor | Board & advisors |
Complete people profiles for Neucyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neucyte
3 dated milestones of Neucyte across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Neucyte is founded.
- Funding First funding round of $6.7M.
- Funding Latest funding round, Grant, of $500K.
Competitors of Neucyte
Neucyte has 3 listed competitors in our database, 2 of them funded. They include Vivodyne, NextVivo and Adapsyn.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | Developer of AI-based platform for lab-grown human tissues | ||
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. | |
| adapsyn.com | 2016 | Hamilton, United States | Provider of computational tools for bacterial metabolomic and genomic data analysis |
Detailed competitors of Neucyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neucyte
The website of Neucyte (neucyte.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 265.6% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Neucyte (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neucyte
Complete news archive for Neucyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neucyte
Neucyte was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Neucyte is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Neucyte is a funded company, having raised a total of $6.7M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.7M, raised on May 2018.
Neucyte has 10 employees.
Neucyte was founded in 2015 and is located in Sunnyvale, United States, within the biotechnology sector focused on neuroscience. Reprogramming technology is utilized to generate homogenous populations of various neuronal subtypes. Human neural in vitro systems are offered for evaluating higher-order electrophysiology, which aids in predicting drug efficacy and assessing potential CNS safety or toxicology risks. Human-specific neural phenotypes are examined through this platform, features absent in animal models.
Neucyte offers SynFire Technology and MaxTwo Microelectrode Arrays.
Neucyte has 3 investors. Key investors include HHS, Co-win Ventures, and Leaguer.
Neucyte operates through Neucyte, Inc..